NINGBO INNO PHARMCHEM CO.,LTD. is at the forefront of exploring the complex role of metabolites in human health, including Phenylacetylglutamine (CAS 28047-15-6). This compound, primarily formed through the conjugation of phenylacetate and glutamine, is gaining recognition not only for its function in nitrogen excretion but also as a metabolite deeply influenced by the gut microbiota.

Recent scientific discourse highlights Phenylacetylglutamine as a key player in the gut-microbiota-host interaction. The gut microbiota metabolizes certain dietary components and host molecules, producing a range of metabolites that can influence systemic health. Phenylacetylglutamine is one such metabolite that is increasingly studied for its impact on human physiology, particularly in relation to aging and the development of chronic diseases.

Research indicates that phenylacetylglutamine and aging are closely correlated, with higher urinary concentrations often observed in older individuals. This suggests that alterations in gut microbial activity and metabolic pathways over time contribute to its accumulation. Understanding these dynamics is crucial for developing interventions that promote healthy aging.

Furthermore, Phenylacetylglutamine has been implicated in the pathogenesis of cardiovascular diseases. Studies suggest a link between gut-microbiota-dependent Phenylacetylglutamine and cardiovascular conditions, potentially through mechanisms involving adrenergic receptors. This makes it an important target for research aimed at preventing and managing heart disease. The ongoing exploration of phenylacetylglutamine metabolite excretion provides deeper insights into these connections.

As a vital component in understanding these intricate biological processes, NINGBO INNO PHARMCHEM CO.,LTD. provides high-purity Phenylacetylglutamine for research purposes. By supplying this crucial compound, we aim to support scientists in their investigations into the gut microbiota's influence on metabolic health, aging, and cardiovascular well-being. The study of phenylacetylglutamine as a biomarker for metabolic age continues to be a promising avenue for future health discoveries.